Zacks.com on MSN3d
Vertex Down 13% in 6 Months: Buy, Sell or Hold the Stock?
The stock of Vertex Pharmaceuticals Incorporated VRTX has declined almost 13% in the past six months. A key reason for the stock price decline was unimpressive data from a phase II study on its key ...
STAT3d
Tris Pharma, looking to compete with Vertex, reports acute pain trial success
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...
Hosted on MSN3d
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...
STAT4d
Chinese biotech says it will start first in vivo beta-thalassemia trial
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
PharmiWeb4d
Advancing the development of CRISPR platform technologies
Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts
Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.